PIK3CA and neoplasm: The goals of this pilot trial were to examine the safety and efficacy of combined PIK3CA and TORC1/2 inhibition with PIKTOR, followed by cis/nab pac chemotherapy in patients with metastatic TNBC, and to investigate whether dual inhibition of the PI3K pathway would increase DDR deficiency and tumor immunogenicity.